Contribute Try STAT+ Today

Good morning, everyone, and welcome to the middle of the week. Given that so many of us are confined at home, it may not feel that way, since it is much easier for the days to simply become a blur, but here we are. We can relate, at least to an extent. We have toiled on the mostly tranquil Pharmalot campus for much of the past 13 years, although our short person is now with us round the clock. So like you, there are adjustments. But certain things do not change, such as firing up the coffee kettle. So here we go. Meanwhile, here are some tidbits. As always, stay safe and stay in touch.

Trump administration officials are asking India to lift restrictions to give the U.S. access to pharmaceutical ingredients to produce a range of drugs amid fears of a U.S. shortage of medicines prompted by the coronavirus outbreak, NBC News reports. The two governments are holding discussions aimed at easing new restrictions on pharmaceutical exports from India, which New Delhi introduced to ensure that the country would have medicine needed to handle the pandemic inside its borders.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.